Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPriority Health Medicare Formulary Coverage | Open…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentPriority HealthPolicy N/A

    Priority Health Medicare MPSERS Formulary (Drug List) — Coverage Criteria

    Customize your policy alerts

    Sign up for all priority health policy alerts

    Know when priority health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document governs the covered prescription drugs, coverage rules (prior authorization, quantity limits, step therapy), and member processes for Priority Health Medicare MPSERS plan members and their prescribers.

    Policy Summary
    PayerPriority Health
    PolicyPriority Health Medicare MPSERS Formulary (Drug List) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewApr 21, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when a drug is marked 'PA' to avoid denial of coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    May 1, 2026formulary current as of
    4/21/2026formulary last updated
    30 daystemporary supply for restricted drugs
    PA, QL, ST, HIutilization management types
    T1-T6tiers represented

    Formulary Coverage Rules

    General formulary coverage

    Covered when ALL of the following are met

    Standard coverage conditions: Drug is listed on the Priority Health Medicare formulary and is medically necessary; the prescription is filled at a Priority Health Medicare network pharmacy; and other plan rules (e.g., PA, QL, ST, B/D, HI) are followed.

    See Evidence of Coverage for filling details and temporary transition supply rules (30-day transition supply for non-formulary/restricted drugs).

    Per-drug coverage with utilization management

    Coverage and utilization management indicated per drug entry when ALL of the following fields are present

    Formulary entry must include: Drug name, dosage/form, tier assignment, and Requirements/Limits (e.g., PA, QL, HI, ST) are present on the formulary row.

    The drug is covered according to its tier and is subject to the listed utilization management controls.

    Policy Summary
    PayerPriority Health
    PolicyPriority Health Medicare MPSERS Formulary (Drug List) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewApr 21, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when a drug is marked 'PA' to avoid denial of coverage.
    SourceLink
    On This Page
    Formulary Coverage RulesDrug List and Coding IndicatorsRequired Provider Steps and Denial RisksInitial Therapy and Entry RequirementsQuantity Limits by ProductSite-of-Care and Benefit DeterminationFormulary Abbreviations and Tier DefinitionsPolicy Background and Scope

    General coverage rules

    Coverage is determined by drug tier and any associated utilization management controls specified per drug/formulation.

    General formulary rules: Drugs are covered according to their assigned tier (T1–T6) but may require prior authorization (PA), be subject to quantity limits (QL), step therapy (ST), or be designated Part B vs Part D (B/D) or Home Infusion (HI) as listed.

    Examples in the formulary show anticonvulsants, antidementia agents, and antidepressants with PA/QL/ST flags; follow the per-drug Requirements/Limits for operational coverage.

    Formulary administrative criteria

    Coverage is indicated per formulary tier with administrative conditions

    Administrative coverage flags: Each drug is assigned a formulary tier (T1–T6) and may carry administrative flags such as PA (Prior Authorization), QL (Quantity Limits), LA (Limited Availability), HI (Home Infusion) or ST (Step Therapy) which must be met for coverage.

    Tier 5 specialty drugs are limited to a 30-day supply as an administrative rule.

    Formulary coverage constraints

    Coverage and restrictions for listed drugs:

    drugs_requiring_PA: Drugs listed with 'Requirements/Limits = PA' require prior authorization before coverage will be approved.

    Many oncology and specialty agents (examples: PEMAZYRE, PIQRAY, ROZLYTREK, REVUFORJ, VITRAKVI, VERZENIO) are marked PA in the formulary.

    drugs_with_quantity_limits: Drugs with 'QL' are limited to the stated quantity within the specified time period and claims exceeding QL may be denied or limited.See individual formulary QL entries (e.g., PEMAZYRE QL 14 EA per 21 days; PIQRAY 200 mg QL 28 EA per 28 days; REVUFORJ 110 mg QL 120 EA per 30 days)

    Quantity limits are enforced per product and presentation.

    tier5_supply_limit: Tier 5 (specialty) drugs are administratively limited to a 30-day supply only.30-day supply

    Document notes this supply limitation for Tier 5 items.

    limited_availability_flag: Drugs marked 'LA' (Limited Availability) may have special access or distribution constraints affecting coverage.

    Examples in the formulary include agents with LA noted alongside PA/QL.

    General coverage conditional on PA/QL listed

    Coverage and requirements as listed per formulary entry

    Formulary entry coverage rules: Coverage for each listed drug is conditional on its tier and any Requirements/Limits shown on the formulary row; items marked PA require prior authorization and items with QL are limited to the stated quantity per timeframe.

    Specific clinical PA criteria or exception processes are referenced elsewhere; providers must follow the plan's PA and QL processes.

    Coverage rules (tier assignment with PA/QL)

    Coverage posture is tier-based with additional restrictions as noted.

    Formulary assignment and restrictions: Drugs are assigned to tiers T1–T6; many drugs—particularly specialty (T5) and certain higher-cost agents—require prior authorization and/or have quantity limits as specified next to each drug.

    Providers must obtain PA where indicated and ensure dispensed quantities do not exceed the listed QL for each product.

    Formulary management criteria

    Coverage/management rules indicated by flags (PA, QL, ED, ST, LA, HI) applied to listed products.

    Formulary management: Drugs on the formulary must be managed according to the flags shown (PA, QL, ED, ST, LA, HI). When PA is listed, prior authorization is required; when QL is listed, dispense quantities must align with the limit; items marked ED are excluded from coverage.

    Home infusion (HI) or B/D designations affect site-of-care and billing; see per-drug rows for those flags.

    Standard formulary coverage with utilization management

    Coverage is provided per formulary tier with utilization management; drugs listed are covered according to tier but may require PA or have QL limits.

    Formulary coverage with UM: Drug coverage depends on formulary tier and the application of utilization management controls: apply prior authorization when 'PA' is indicated and adhere to quantity limits (QL) stated per product; some products carry additional flags (LA, HI, ST, B/D) that modify coverage or site-of-care billing.See individual QL and PA entries in the formulary rows

    Specific PA submission requirements and clinical criteria are located in the plan's prior authorization guidelines and on referenced formulary pages.

    Entries labeled ED (Excluded Drug) are drugs that the Medicare Prescription Drug Plan does not normally cover. When a drug is designated ED, the member’s cost-sharing for that drug does not count toward their total drug costs and therefore does not help the member qualify for catastrophic coverage or receive additional 'extra help' subsidies.

    Excluded drugs (ED) do not count toward catastrophic coverage; amounts a member pays for an ED drug are excluded from the total drug cost calculation used to determine qualification for catastrophic benefits.

    Within this extract the legend defines ED (Excluded Drug), but the pages shown do not attach the ED flag to many specific formulary rows in these chunks. The document notes abbreviations and that full abbreviation definitions begin on page 10.

    Specialty products assigned to Tier 5 are administratively limited to a 30-day supply. The formulary legend and multiple drug entries reiterate the Tier 5 = 30-day supply only policy; some Tier 5 rows also carry flags such as ED or NE elsewhere in the full formulary.

    Although many product rows appear in the extract, there is no single contiguous list of explicitly excluded drugs in these chunks. Some individual items elsewhere in the document are marked ED, but the displayed excerpts do not present a complete excluded-drug list.

    The abbreviation ED (Excluded Drug) is present in the formulary legend and used in several rows in the full document, but the specific excluded products are not comprehensively listed within this excerpt.

    An administrative supply limitation applies to specialty drugs: Tier 5 drugs are limited to a 30-day supply only. This is an operational rule noted in the legend and applied to Tier 5 entries.

    This extract does not include explicit 'not medically necessary' (NMN) determinations for drugs. Instead, coverage limitations in the excerpt appear as administrative flags (for example, PA, QL, ED, and ST) applied to specific formulary entries.

    Several products in the listings shown are explicitly marked ED in the document (examples in other pages include topical and vitamin preparations). The extract includes sample rows where ED is applied to specific products.

    Entries marked ED are excluded from coverage under the Medicare Prescription Drug Plan. The formulary uses ED to denote products that will generally not be covered and may be denied at claim processing.

    The presence of the ED flag next to a product indicates the plan considers that product excluded and not payable under the Part D formulary. Examples of product lines elsewhere in the document show ED applied to certain topical agents and nutritional/vitamin products.

    For the drugs displayed in the provided excerpt, no comprehensive excluded-drug list is presented. The extract includes the ED definition and some rows with ED, but many shown entries do not carry explicit exclusion markings within these chunks.

    No explicit statements declaring drugs as 'not medically necessary' appear in these chunks. Coverage constraints are expressed through administrative flags and the formulary’s Requirements/Limits columns rather than NMN language in this excerpt.

    Coverage and utilization restrictions in the extract are implemented via requirement/limit flags — PA (Prior Authorization), QL (Quantity Limits), ST (Step Therapy), ED (Excluded Drug) and other abbreviations — rather than explicit 'not medically necessary' rulings in the text shown.

    Drug List and Coding Indicators

    Formulary - NSAIDs and Analgesics (selected)mixed
    diclofenac sodium erListed as diclofenac sodium er (Non-preferred, Tier 4)
    diclofenac potassium 50 mg tabletListed as diclofenac potassium oral tablet 50 mg (Tier 2)
    diclofenac sodium external solution 1.5%Topical diclofenac sodium external solution 1.5% (Tier 4) - QL 750 ML per 30 days
    diclofenac delayed release 50 mg, 75 mgdiclofenac sodium oral tablet delayed release 50 mg, 75 mg (Tier 2)
    diclofenac-misoprostol drdiclofenac-misoprostol oral tablet delayed release (Tier 4)
    celecoxib oralcelecoxib oral (Tier 2)
    ibuprofen oral tablet 400 mg, 600 mg, 800 mgIBU oral tablet 400 mg, 600 mg, 800 mg (Generic Tier 2)
    ibuprofen oral suspension 100 mg/5mlibuprofen oral suspension 100 mg/5 mL (Tier 4)
    Formulary - Drug list (extract)mixed
    celecoxib oralcelecoxib — Tier 2
    diclofenac potassium 50 mg tabletdiclofenac potassium 50 mg — Tier 2
    diclofenac sodium erdiclofenac sodium er — Tier 4
    diclofenac sodium external solution 1.5%Topical diclofenac 1.5% — Tier 4; QL 750 ML per 30 days
    ibuprofen oral tablet 400 mg, 600 mg, 800 mgibuprofen oral tablets 400/600/800 mg — Tier 2
    ibuprofen oral suspension 100 mg/5mlibuprofen suspension 100 mg/5 mL — Tier 4
    mefenamic acid oralmefenamic acid — Tier 4; QL 30 EA per 30 days
    meloxicam oral tabletmeloxicam — Tier 1
    Formulary - Quantity limits examplesmixed
    mefenamic acidQL (30 EA per 30 days)
    linezolid oral tabletQL (56 EA per 28 days)
    Formulary - No explicit codesmixed
    No codes listed
    Coding legend abbreviationsmixed
    PAPrior Authorization
    QLQuantity Limits
    STStep Therapy
    LALimited Availability
    B/DPart B vs. Part D
    EAEach
    EDExcluded Drug
    HIHome Infusion
    NENo Express Scripts
    MLMilliliters
    1–10 of 11
    1/2
    Selected entries - endocrine/diabetesmixed
    RYBELSUSRYBELSUS — PA; QL (30 EA per 30 days)
    FIASP PENFILLFIASP PENFILL — listed
    HUMALOGHUMALOG products — listed
    Cardiovascular / Lipid agents (selected)mixed
    benazepril hcl 20 mgbenazepril 20 mg — QL (120 EA per 30 days)
    ramiprilramipril — various QLs listed
    atorvastatin 10 mgatorvastatin 10 mg — QL (240 EA per 30 days)
    rosuvastatin 10 mgrosuvastatin — QL (120 EA per 30 days)
    Selected formulary products with PA/QLmixed
    fluorouracil external cream 5%fluorouracil external cream 5% — QL (40 GM per 30 days)
    LOKELMA ORAL PACKET 5 GMLOKELMA — QL (30 EA per 30 days)
    Specialty / Rare-disease productsmixed
    tolvaptan oral tablet therapy packtolvaptan — PA; QL (56 EA per 28 days)
    AMVUTTRAAMVUTTRA — PA; QL (0.5 ML per 90 days)
    Dermatologic agents with QLmixed
    fluorouracil external cream 5%QL (40 GM per 30 days)
    tacrolimus ointmenttacrolimus — QL (varies)
    Formulary drug lines (partial list)mixed
    omeprazole oral capsule delayed release 20 mgTier 1 — omeprazole 20 mg — listed
    pantoprazole sodium oral tablet delayed releasepantoprazole — Tier 1
    diclofenac sodium ophthalmicdiclofenac sodium ophthalmic — Tier 2
    ketorolac tromethamine ophthalmic solution 0.5%ketorolac ophthalmic 0.5% — QL (20 ML per 30 days)
    restasis multidose ophthalmic emulsion 0.05%Restasis — QL (5.5 ML per 30 days)

    Required Provider Steps and Denial Risks

    Prior Authorization

    Required Provider Steps and Denial Risks

    Priority Health requires prior authorization (PA) for many listed drugs and drug categories. Prescribers or members must obtain PA before dispensing PA‑marked medications; claims submitted without an approved PA may be denied or not paid. PA triggers include many specialty, high‑cost, oncology, orphan, and select non‑specialty agents (examples in the formulary: XIFAXAN, DIFICID, XCOPRI, AUVELITY, EXXUA, ZURZUVAE, OTEZLA, many oncology oral agents such as VENCLEXTA/VERZENIO/ROZLYTREK, specialty biologics and injectables like DUPIXENT, COSENTYX, HUMIRA, and orphan/specialty agents including AMVUTTRA, ENDARI, NULIBRY, REPATHA, NEXLETOL, EVRYSDI, and others). Quantity limits (QL) are enforced per formulary entries (e.g., 30 EA per 30 days, ML/GM/EA per period); exceeding the listed QL can trigger denial, partial payment, or a requirement to provide additional justification. Some products are Limited Availability (LA), Home Infusion (HI), or excluded (ED/NE) and have special handling or may be denied. Step therapy (ST) requirements apply for selected agents (examples: DIFICID, FETZIMA, TRINTELLIX, febuxostat, paliperidone ER formulations, select ophthalmics) — formulary rows mark ST where it applies; specific program rules are in the full formulary definitions.

    • PA required for selected drugs (formulary rows marked PA)
    • PA required for listed drugs including many Tier 5/specialty agents and select Tier 3–4 branded drugs
    • Prior authorization required before filling PA‑marked prescriptions; lack of PA may lead to denial
    • Prior Authorization required for specialty, oncology, orphan, and high‑cost drugs (examples listed in formulary)
    • PA required for listed PA items such as injectables, pen needles, specialty pens and supplies
    • PA required for specified drugs (examples: XIFAXAN strengths, DIFICID, XCOPRI, AUVELITY, EXXUA, ZURZUVAE)
    • Selected drugs requiring prior authorization: OTEZLA, RELISTOR, many immunologics/biologics, and numerous oncology oral agents
    • Specialty/orphan drugs require PA (examples: AMVUTTRA, ENDARI, NULIBRY, PROLASTIN‑C, REVCOVI, VYNDAMAX)
    • Prior Authorization requirement — claims for PA‑labeled drugs without approval risk denial
    • Prior authorization denial risk: failure to obtain PA may result in non‑coverage or denial of the claim
    • Prior authorization triggers include: specialty tier (T5) designation, certain strengths/forms, LA/HI designations, and formulary PA flags
    • Selected PA triggers called out: XIFAXAN 200mg/550mg, LIDOCANE patches, ESLICARBAZEPINE strengths, RUFNAMIDE, XCOPRI packs, DIHYDROERGOTAMINE nasal
    • Specialty/oncology PA triggers: many oral oncology agents (VENCLEXTA, VERZENIO, ROZLYTREK, PIQRAY, etc.) list PA and QL
    • Prior Authorization indicated on formulary legend (PA abbreviation and explanation provided)
    • Quantity limit exceeding: exceeding QL (EA/ML/GM per time period) may trigger denial or require justification
    • Exclusion/denial triggers: ED (Excluded Drug) and NE entries indicate non‑covered or limited supply channels; market withdrawals may be immediately removed
    • Prescriber supporting statement required when requesting an exception — prescriber must explain medical reasons; standard decision timeline: 72 hours (or 24 hours for expedited requests)
    • Submission of clinical setting/use: B/D (Part B vs Part D) entries require prescriber submission of clinical use/setting to determine coverage
    • Documentation for specialty drugs: Tier 5/specialty drugs have PA and QL; providers must submit PA documentation per payer process
    • PA and QL documentation: prescribers must supply medical necessity documentation and dosing justification to satisfy PA and QL fields
    • Quantity limits documented on formulary: many entries list exact QL (e.g., 30 EA per 30 days, ML per 30 days, GM per 30 days) and must be observed
    • Documentation for PA: prescribers should supply required documentation to satisfy PA/QL/ST/LA fields per formulary notes
    • PA and QL requirements: PA and quantity limits are enforced for many specialty and select non‑specialty agents
    • Quantity limits and LA: Limited Availability products often also have PA and specific QL enforced
    • Formulary abbreviations and documentation guidance: legend explains B/D, PA, QL, ST, LA, NE, ED and tier definitions; consult full formulary definitions beginning on page 10
    • Reference for abbreviations and rules: full definitions and program rules are available in the formulary (see page 10) and online; the formulary was last updated 4/21/2026
    • Step therapy requirements: ST applies where marked — members may be required to try preferred drugs first before coverage of alternatives
    • Step therapy flags (no specific rules in excerpt): ST is indicated in rows but specific step rules are in the full formulary
    • Step therapy for select agents: examples include DIFICID, FETZIMA, TRINTELLIX, febuxostat, paliperidone ER
    • Step therapy referenced: ST referenced in legend and entries; consult full formulary for program details
    • Step therapy notation: products with ST are marked in Requirements/Limits
    • Step therapy noted: select ophthalmics (difluprednate, loteprednol) and others are marked ST
    • Step therapy (legend): ST abbreviation explained in the List of Abbreviations and legend
    • Step therapy (general note): ST abbreviation present; details and exceptions must be referenced in the full program documentation
    • Step therapy for select ophthalmics: difluprednate and loteprednol formulations are marked ST

    Initial Therapy and Entry Requirements

    Initial therapy controls

    Initial therapy controls

    Step therapy examples: Certain agents require step therapy (ST) prior to coverage; members must try specified first-line or preferred drugs before coverage of non-preferred alternatives is approved.

    Examples: DIFICID and selected antidepressants (e.g., FETZIMA, TRINTELLIX) show ST or ST-related flags on formulary rows; where ST is listed, prior steps and documentation must be met per plan process.

    Coverage ruleDetails
    Step therapy required
    Some drugs require step therapy; members must try specified first-line drugs before the plan will cover alternative drugs for the same condition. Check the Requirements/Limits column in the formulary to determine whether ST applies to a specific product.
    Step guidanceNotes
    Try preferred drug(s) first
    ST (Step Therapy) may require members to trial preferred agents before coverage of non-preferred alternatives; if the preferred agent is ineffective or not tolerated, the plan will cover the alternative per formulary procedures.
    ProductStep therapy status
    DIFICID oral suspension (reconstituted)
    Requirements/Limits = ST; QL (136 ML per 10 days)
    DIFICID oral tablet
    Requirements/Limits = ST; QL (20 EA per 10 days)
    ProductsStep therapy status
    FETZIMA
    Requirements/Limits = ST; QL (30 EA per 30 days); NE (not available at Express Scripts) per formulary row
    TRINTELLIX
    Requirements/Limits = ST; QL (30 EA per 30 days); NE per formulary row
    vilazodone
    Listed with ST in formulary rows (step therapy indicated)
    febuxostat
    Listed with ST in formulary rows (step therapy indicated)
    Legend flagImplication
    ST (Step Therapy) flag in formulary legend
    The formulary legend includes ST as an abbreviation meaning Step Therapy, but specific step-therapy sequences or product-level rules are not detailed in this extract; check full formulary for sequences.
    Product groupStep therapy rule
    Paliperidone ER formulations
    Requirements/Limits = ST; QL specified (e.g., 1.5/3/9 mg ST; 30 EA per 30 days; 6 mg ST with QL 60 EA per 30 days) indicating step therapy applies to select extended-release paliperidone products.
    ReferenceDetail
    Abbreviations list includes ST
    Step Therapy (ST) is identified among the requirements/limits abbreviations, but the extract does not provide the specific step sequences for most products.
    ST indicatorDetail
    ST indicates Step Therapy may apply
    Formulary rows show ST as a possible requirement flag; this extract does not provide required step sequences or order of therapies where ST is indicated.
    ProductST note
    Calcitriol external
    Requirements/Limits = ST (step therapy) listed in formulary row; specific step requirements not provided in this excerpt.
    ProductCoverage implication
    Calcitriol external
    Listed with Requirements/Limits = ST; where ST is indicated on the formulary, prior steps must be documented per plan rules (specific steps not shown in this extract).
    Legend referenceNote
    ST referenced in legend
    Step Therapy (ST) is included in the formulary legend/abbreviations, but product-level ST rules are not included in the provided extract.
    AbbreviationPresence
    ST
    Step therapy is defined as an abbreviation (ST) in the formulary legend; the extract does not include the detailed step therapy criteria or required prior agents.
    Ophthalmic productStep therapy status
    difluprednate (ophthalmic)
    Requirements/Limits = ST (step therapy) as shown in formulary rows for ophthalmic anti-inflammatories.
    loteprednol formulations (ophthalmic gel/suspension)
    Requirements/Limits = ST (step therapy) listed for multiple loteprednol presentations in the formulary.

    Quantity Limits by Product

    inv-144: XARELTO 10MG (example) — per-prescription limit
    Per-prescription example (tablet count)XARELTO 10 mg: 30 tablets per prescription (example shown in formulary explanatory text).
    Monthly EA exampleXARELTO oral tablet 10 mg QL = 30 EA per 30 days for standard tablet dosing.
    Suspension recon ML exampleXARELTO oral suspension (reconstituted) QL = 620 ML per 30 days for liquid presentation.
    inv-145: Multiple QL examples across products
    High-volume ML limitsExamples include QL (900 ML per 30 days) for some oral solutions and QL (2400 ML per 30 days) for high-volume liquid opioids.
    Opioid tablet EA limitsCommon QLs for opioid tablets: 60 EA per 30 days, 120 EA per 30 days, or 360 EA per 30 days depending on product.
    Patch/count limitsFentanyl transdermal patch QL example = 10 EA per 30 days.
    inv-146: linezolid oral tablet QL example
    Linezolid oral tablet QLLinezolid oral tablet QL = 56 EA per 28 days.
    Linezolid formulations notedLinezolid also listed as IV solution and oral suspension in formulary rows (different tiers).
    Use-caseTablet QL is strength/formulation-specific and enforced per 28-day period.
    inv-147: vancomycin HCl oral capsule 125 mg QL
    Vancomycin oral capsule 125 mgQL = 80 EA per 30 days.
    Vancomycin oral capsule 250 mgQL = 160 EA per 30 days.
    Vancomycin IV (HI) entriesMultiple IV reconstituted strengths are listed with HI (home infusion) requirement in formulary rows.
    inv-148: vancomycin HCl oral capsule 250 mg QL
    Vancomycin oral capsule 250 mgQL = 160 EA per 30 days.
    ContextOral capsule QLs differ by strength; IV formulations flagged HI.
    Enforcement periodQL expressed as EA per 30 days for capsules.
    inv-149: XIFAXAN 200 mg QL
    XIFAXAN 200 mg tabletQL = 9 EA per 30 days.
    Formulary noteXIFAXAN 200 mg requires PA and has a 9 EA per 30 days limit.
    Comparative strengthHigher-strength XIFAXAN 550 mg has a larger QL (60 EA per 30 days) and may be subject to PA as well.
    inv-150: XIFAXAN 550 mg QL
    XIFAXAN 550 mg tabletQL = 60 EA per 30 days.
    Prior authorizationXIFAXAN 550 mg is listed with PA and QL in the formulary.
    Strength-dependent QLDifferent strengths have distinct QLs (200 mg = 9 EA; 550 mg = 60 EA per 30 days).
    inv-151: DIFICID oral suspension QL
    DIFICID oral suspensionQL = 136 ML per 10 days.
    Associated requirementDIFICID oral suspension requires Step Therapy (ST) in addition to the QL.
    Dose-limited courseQL expressed over 10-day period consistent with typical fidaxomicin course lengths.
    inv-152: DIFICID oral tablet QL
    DIFICID oral tabletQL = 20 EA per 10 days.
    Step therapyDIFICID oral tablet entry shows ST and QL together in formulary row.
    Course-based limitQL reflects short-course treatment period (10 days).
    inv-153: XCOPRI oral tablet QL examples
    XCOPRI therapy pack QLXCOPRI therapy pack QL = 56 EA per 28 days (therapy-pack presentations).
    XCOPRI standard strengthsXCOPRI 100/25/50/150/200 mg entries list QLs such as 30 EA per 30 days or 60 EA per 30 days depending on strength.
    PA requirementXCOPRI entries indicate PA plus strength-specific QLs.
    inv-154: eslicarbazepine acetate QL examples
    Eslicarbazepine acetate200/400 mg: QL = 30 EA per 30 days; 600/800 mg: QL = 60 EA per 30 days.
    PA indicatedEslicarbazepine acetate entries list PA plus QL as requirements for coverage.
    Strength-tier relationshipHigher strengths have larger monthly EA allowances.
    inv-155: memantine formulations QL examples
    Memantine tablet QLMemantine oral tablet QL = 60 EA per 30 days.
    Memantine solution QLMemantine oral solution QL = 300 ML per 30 days.
    Pack-specific QLSpecific combination pack QL = 49 EA per 28 days (formulation-dependent).
    inv-156: dihydroergotamine mesylate nasal QL
    Dihydroergotamine nasalDihydroergotamine mesylate nasal QL = 8 ML per 30 days.
    Usage frequencyML-based QL appropriate for nasal/solution presentations over 30-day period.
    Associated PA flagsSome migraine agents also carry PA or ST flags in formulary rows.
    inv-157: abiraterone acetate QL example
    Abiraterone acetateQL = 120 EA per 30 days.
    Oncology presentationAbiraterone acetate listed as a specialty oncology agent with numeric monthly QL.
    Dose-pack limitsQL expressed as EA per 30 days consistent with oral oncology regimens.
    inv-158: ERLEADA/XTANDI examples and other oncology QLs
    ERLEADA / XTANDI and othersExamples: ERLEADA 240 mg QL = 30 EA per 30 days; ERLEADA 60 mg QL = 120 EA per 30 days; many oncology agents list PA + numeric QLs.
    Oncology QL patternsOral oncology agents commonly show strength-specific EA-per-period limits (28/30-day or 21-day windows).
    LA flagsSome oncology agents include Limited Availability (LA) in addition to PA and QL.
    inv-159: PEMAZYRE QL
    PEMAZYRE QLPEMAZYRE QL = 14 EA per 21 days.
    Specialty tierPEMAZYRE is listed as a Tier 5 specialty agent with PA and QL.
    Short-interval QLQL specified over a 21-day interval reflecting dosing schedule.
    inv-160: PIQRAY 200 mg daily-dose QL
    PIQRAY 200 mg daily-doseQL = 28 EA per 28 days (200 mg daily-dose presentation).
    Higher-strength PIQRAY250 mg and 300 mg presentations list QL = 56 EA per 28 days in the formulary.
    PA associationPIQRAY entries include PA plus strength-specific QLs.
    inv-161: PIQRAY higher-strength QLs
    PIQRAY higher strengthsPIQRAY 250 mg & 300 mg QL = 56 EA per 28 days.
    Consistency noteHigher-dose presentations often have larger EA allowances per interval.
    PA & LA metadataSome PIQRAY entries are subject to PA and may include LA flags for certain forms.
    inv-162: QINLOCK QL
    QINLOCK QLQINLOCK QL = 90 EA per 30 days.
    PA requirementQINLOCK entry lists PA in Requirements/Limits alongside the QL.
    Specialty-tier patternQINLOCK is a Tier 5 agent with a numeric monthly EA limit.
    inv-163: REVUFORJ (110 mg) QL
    REVUFORJ 110 mgQL = 120 EA per 30 days.
    REVUFORJ other strengths160 mg QL = 60 EA per 30 days; 25 mg QL = 240 EA per 30 days (strength-specific QLs).
    PA presenceREVUFORJ entries include PA plus the numeric QLs.
    inv-164: REVUFORJ (160 mg) QL
    REVUFORJ 160 mgQL = 60 EA per 30 days.
    Comparative strengthsOther strengths have different QLs (110 mg = 120 EA; 25 mg = 240 EA per 30 days).
    Oncology QL normsREVUFORJ examples show typical oncology per-month EA caps tied to strength.
    inv-165: REVUFORJ (25 mg) QL
    REVUFORJ 25 mgQL = 240 EA per 30 days.
    Dose-range noteLowest-strength presentation may have higher EA counts reflecting dosing frequency differences.
    PA & QL enforcementREVUFORJ entries include PA with QL to govern coverage and dispensing.
    inv-166: REZLIDHIA QL
    REZLIDHIA QLREZLIDHIA QL = 60 EA per 30 days.
    PA requirementREZLIDHIA listed with PA alongside the QL in formulary rows.
    Specialty-tier QL patternMany specialty drugs list similar monthly EA caps tied to therapy duration.
    inv-167: ROMVIMZA QL
    ROMVIMZA QLROMVIMZA QL = 8 EA per 28 days.
    PA notedROMVIMZA entry includes PA with the QL for coverage control.
    Short-interval oncology QLSome agents use 28-day QL periods (e.g., ROMVIMZA 8 EA/28 days).
    inv-168: ROZLYTREK 100 mg QL
    ROZLYTREK 100 mgQL = 150 EA per 30 days.
    ROZLYTREK 200 mgQL = 90 EA per 30 days (different strength different QL).
    ROZLYTREK packetROZLYTREK oral packet QL = 336 EA per 28 days for packet presentation.
    inv-169: ROZLYTREK 200 mg QL
    ROZLYTREK 200 mgQL = 90 EA per 30 days.
    Packaging effectDifferent presentations (capsule vs packet) have distinct QLs in the formulary.
    PA presenceROZLYTREK entries include PA alongside QLs.
    inv-170: ROZLYTREK oral packet QL
    ROZLYTREK oral packetQL = 336 EA per 28 days.
    Packet-specific QLTherapy-packet presentations often list large EA counts per 28-day period.
    Coverage controlPA + QL applied to packet presentations similar to capsule forms.
    inv-171: RUBRACA QL
    RUBRACA QLRUBRACA QL = 120 EA per 30 days.
    PA indicatedRUBRACA listed with PA and numeric monthly QL.
    Oncology specialty patternConsistent with other oncology agents, PA + QL applied.
    inv-172: RYDAPT QL
    RYDAPT QLRYDAPT QL = 224 EA per 28 days.
    PA notedRYDAPT entry includes PA with QL in formulary listing.
    Large-count QLsSome agents have high EA allowances over 28-day intervals reflecting dosing regimens.
    inv-173: SCEMBLIX (100 mg) QL
    SCEMBLIX 100 mg QLSCEMBLIX 100 mg QL = 120 EA per 30 days.
    SCEMBLIX other strengths20 mg QL = 60 EA per 30 days; 40 mg QL = 240 EA per 30 days.
    PA requirementSCEMBLIX entries include PA plus QLs by strength.
    inv-174: SCEMBLIX (20 mg) QL
    SCEMBLIX 20 mgQL = 60 EA per 30 days.
    SCEMBLIX dosing rangeDifferent strengths have proportionate QLs reflecting dosing schedules.
    Administrative notePA applies across strengths with distinct numeric caps.
    inv-175: SCEMBLIX (40 mg) QL
    SCEMBLIX 40 mgQL = 240 EA per 30 days.
    High-count strengthHigher-strength presentations can carry larger monthly EA allowances.
    Coverage controlPA + QL govern access to these specialty agents.
    inv-176: STIVARGA QL
    STIVARGA QLSTIVARGA QL = 84 EA per 28 days.
    LA flagSTIVARGA entry includes LA in addition to PA and QL for some presentations.
    Interval-specific QL28-day QLs commonly used for certain oncology agents.
    inv-177: sunitinib malate QL
    Sunitinib malate QLSunitinib malate QL = 30 EA per 30 days.
    PA flagSunitinib entry includes PA; QL limits monthly dispensing.
    Standard oncology patternStrength-specific QLs and PA common across targeted therapies.
    inv-178: TABRECTA QL
    TABRECTA QLTABRECTA QL = 120 EA per 30 days.
    PA associationTABRECTA listed with PA and numeric monthly QL.
    Oncology dosing alignmentQL reflects typical monthly supply for oral oncology regimens.
    inv-179: RYBELSUS QL
    RYBELSUS QLRYBELSUS QL = 30 EA per 30 days.
    PA notedRYBELSUS entries list PA plus a 30 EA per 30 days QL.
    Typical diabetic oral QLCommon monthly EA limits for oral diabetes agents.
    inv-180: TRULICITY QL
    TRULICITY QL (injectable)TRULICITY subcutaneous auto-injector QL = 2 ML per 28 days.
    PA indicatorTRULICITY row lists PA along with the ML-based QL in some formulations.
    Dose-interval relevanceML-based QLs used for injectables to control monthly dosing supply.
    inv-181: enoxaparin prefilled syringes QL
    Enoxaparin prefilled syringes QLQL varies by strength; example: 100 mg/mL prefilled syringes QL = 60 ML per 30 days.
    Strength-dependent ML capsDifferent syringe concentrations have proportionate ML-per-month QLs (e.g., 48 ML, 18 ML examples for other strengths).
    Home infusion vs pharmacySome parenteral products carry HI or B/D indicators that affect site-of-care and coverage handling.
    inv-182: XARELTO oral suspension recon QL
    XARELTO suspension recon QLXARELTO oral suspension (reconstituted) QL = 620 ML per 30 days.
    Tablet QL comparatorsXARELTO tablet 10 mg QL = 30 EA per 30 days; suspension uses ML-based QL for liquid form.
    Formulation-specific limitsDifferent presentations (tablet vs suspension) have distinct QL units (EA vs ML).
    inv-183: Multiple QL examples — varies by drug and strength
    Varied QLs by product/strengthFormulary contains numerous examples: 480 EA/30 days, 240 EA/30 days, 60 EA/30 days, 30 EA/30 days and ML-based QLs for injectables/solutions.
    Strength and presentation matterQL depends on both strength and presentation (tablet, pack, suspension, injection).
    PA commonly paired with QLMany entries list PA alongside QL to manage utilization for higher-cost agents.
    inv-184: rosuvastatin calcium 5/10 mg QL
    Rosuvastatin 5/10 mg QLQL = 120 EA per 30 days.
    Rosuvastatin 20 mg QLQL = 60 EA per 30 days.
    Rosuvastatin 40 mg QLQL = 30 EA per 30 days; strength-specific reductions for higher doses.
    inv-185: rosuvastatin calcium 20 mg QL
    Rosuvastatin 20 mgQL = 60 EA per 30 days.
    Tier and QL linkageStatin QLs tied to common daily dosing and refill frequency.
    Coverage enforcementQLs enforced per 30-day period as listed in formulary rows.
    inv-186: rosuvastatin calcium 40 mg QL
    Rosuvastatin 40 mgQL = 30 EA per 30 days.
    Higher-dose limitationHigher-strength statin QLs are lower EA counts reflecting greater per-tablet potency.
    Standard monthly periodQLs expressed per 30 days for statins in this formulary.
    inv-187: ezetimibe-simvastatin QL
    Ezetimibe-simvastatin QLEzetimibe-simvastatin QL = 30 EA per 30 days.
    Combination product QLCombination lipid agents have standard monthly EA caps similar to monotherapy products.
    Tier assignmentEzetimibe-simvastatin is listed as Tier 2 with the stated QL.
    inv-188: REPATHA QL by presentation
    REPATHA presentation-based QLsREPATHA QL examples: 2 mL per 28 days or 3.5 mL per 30 days depending on the presentation.
    PA + QLREPATHA entries include PA and ML-based QLs tied to presentation/delivery method.
    Injectable ML unitsBiologic injectables commonly use mL units for QLs rather than EA.
    inv-189: AUSTEDO products QL examples
    AUSTEDO QL varietyAUSTEDO QLs vary by strength/presentation (examples include 120, 60, 30, 28 EA per 30 days depending on product).
    PA across strengthsAUSTEDO entries list PA with strength-specific QLs in the formulary.
    Therapy-pack exceptionsSome extended-release or XR presentations have distinct QLs compared with immediate-release forms.
    inv-190: fluorouracil cream 5% QL
    Fluorouracil cream 5% QLQL = 40 GM per 30 days.
    Tacrolimus ointment QLQL = 100 GM per 30 days.
    Topical QL unitsDermatologic agents use GM (grams) or ML (milliliters) for QLs depending on formulation.
    inv-191: tacrolimus ointment QL
    Tacrolimus external ointmentQL = 100 GM per 30 days.
    Formulation-specific QLTopical immunomodulators and calcineurin inhibitors use gram-based limits.
    Coverage notesPA/ST may apply to some dermatologic specialty agents though tacrolimus here is a QL only entry.
    inv-192: LOKELMA oral packet QL
    LOKELMA oral packet 10 gmQL = 90 EA per 30 days.
    Packet-size QLOral packet presentations specified as EA per month.
    Comparative 5 gm packetLOKELMA 5 GM packet QL = 30 EA per 30 days (distinct from 10 GM pack).
    inv-193: RELISTOR ORAL QL
    RELISTOR ORAL QLRELISTOR ORAL QL = 90 EA per 30 days.
    PA requirementRELISTOR is Tier 5 and requires PA in addition to the QL.
    Specialty oral agent patternMany specialty oral agents have monthly EA caps and PA flags.
    inv-194: AMVUTTRA QL
    AMVUTTRA QLAMVUTTRA QL = 0.5 ML per 90 days (listed as per 90-day course).
    PA flagAMVUTTRA entry includes PA; QL expressed per treatment course rather than per 30 days.
    Specialty rare-disease patternsSome rare-disease therapies express QLs over multi-month windows (e.g., per 90 days).
    inv-195: ENDARI QL
    ENDARI QLENDARI QL = 180 EA per 30 days.
    PA notedENDARI is Tier 5 with PA and the stated monthly EA cap.
    Rare-disease supplyHigh EA monthly allowances reflect chronic specialty therapy needs.
    inv-196: VYNDAMAX QL
    VYNDAMAX QLVYNDAMAX QL = 30 EA per 30 days.
    PA requirementVYNDAMAX entry lists PA with the monthly EA limit.
    Tier 5 patternMany specialty agents with PA also carry monthly EA caps in the formulary.
    inv-197: MYRBETRIQ QL (suspension/tablet)
    MYRBETRIQ suspension/tablet QLMYRBETRIQ oral suspension QL = 300 ML per 30 days; MYRBETRIQ oral tablet QL = 30 EA per 30 days.
    Formulation differencesDifferent formulations of same drug can have different QL units (ML vs EA) and values.
    Coverage enforcementQL enforced per 30-day period unless otherwise specified.
    inv-198: Multiple specialty biologics QLs (COSENTYX, DUPIXENT, SKYRIZI, etc.)
    Specialty biologics QL varianceBiologic QLs vary by product and presentation (examples: COSENTYX QL 8 ML per 28 days; DUPIXENT QL 3.42 ML/8 ML per 30 days; SKYRIZI QL 1–2.4 ML per 28/56 days).
    PA commonMost specialty biologics require PA in addition to ML/EA QLs.
    Presentation-driven limitsPrefilled syringes, cartridges, and pens have distinct QLs tied to mL per interval.
    inv-199: HAEGARDA, icatibant, SAJAZIR QL/PA notes
    HAEGARDA and icatibant/SAJAZIRHAEGARDA requires PA; icatibant and SAJAZIR QL = 18 ML per 30 days.
    Angioedema agent patternThese agents are specialty-tier with ML-based QLs and PA to manage dosing supply.
    Manufacturer/presentation notesFormulary entries specify presentation and per-30-day ML caps for consistency.
    inv-200: Multiple QL examples summary
    Examples of atypical intervalsSelected examples include QLs with long intervals: 1 EA per 365 days (vaccines) and 1 ML per 999 days (SHINGRIX presentation).
    Rare multi-year QLsVaccines and specific specialty packs may use multi-year or yearly QLs (e.g., 1 EA per 365 days; 2 EA per 999 days).
    Representative miscellaneous QLsExamples across sections: 30 EA per 30 days; 41 EA per 28 days; 1 ML per 999 days; 2 EA per 720 days — illustrating variability in QL periods.
    inv-201: cinacalcet HCl QL
    Cinacalcet HCl (30/90 mg)QL = 120 EA per 30 days.
    B/D indicatorCinacalcet entries include B/D (Part B vs Part D) and numeric monthly QL.
    Usage contextHigh-count QLs for chronic metabolic agents reflect ongoing therapy needs.
    inv-202: risedronate sodium 150 mg QL
    Risedronate sodium 150 mg QLQL = 1 EA per 28 days.
    BMD agent patternSome bone-metabolism therapies use low-frequency EA-per-period QLs (weekly/monthly equivalents).
    Alternative pack QLsOther risedronate presentations show QLs of 4 EA per 28 days or 30 EA per 30 days depending on strength.

    Site-of-Care and Benefit Determination

    Note
    Note
    Note
    Note
    Note

    Formulary Abbreviations and Tier Definitions

    inv-106: Generic drug definition
    QL definition (abbreviation)QL = Quantity Limit — maximum quantity allowed in the specified time period as noted (e.g., QL (56 EA per 28 days)).
    Units usedCommon units in QL entries: EA (each), ML (milliliters), GM (grams).
    PurposeQLs limit covered quantity per time interval and are enforced per formulary listing.

    Policy Background and Scope

    This formulary lists covered prescription drugs and biologics (including biosimilars) for the Priority Health Medicare MPSERS plan. Drugs are grouped by therapeutic class and each entry shows tier assignment and any applicable administrative controls (for example, PA, QL, ST, ED, or HI). Coverage follows tier-based rules and the Requirements/Limits shown next to each drug.